Objectives Anaplastic lymphoma kinase (ALK) rearrangement status examination has been
widely used in clinic for non-small cell lung cancer (NSCLC) patients in order to find patients …

Objectives: To predict the anaplastic lymphoma kinase (ALK) mutations in lung
adenocarcinoma patients non-invasively with machine learning models that combine …

Purpose This study aimed to investigate the deep learning model (DLM) combining
computed tomography (CT) images and clinicopathological information for predicting …

Purpose To present a radiogenomic computed tomographic (CT) characterization of
anaplastic lymphoma kinase (ALK)-rearranged non–small cell lung cancer (NSCLC)(ALK+) …

Objectives Anaplastic lymphoma kinase (ALK) rearrangement is a validated predictive
marker to define patients with non-small cell lung cancer (NSCLC) who can benefit from …

Introduction Several studies have suggested that non–small-cell lung cancer (NSCLC)
patients who harbor anaplastic lymphoma kinase (ALK) rearrangement might have different …

Objectives To develop and validate the imbalanced data correction based PET/CT radiomics
model for predicting lymph node metastasis (LNM) in clinical stage T1 lung adenocarcinoma …

Right detection of anaplastic lymphoma kinase (ALK) gene rearrangement is pivotal to
selection of patients with lung adenocarcinoma for ALK-targeted therapy. We explored the …

Background Radiogenomic features are predictive of anaplastic lymphoma kinase (ALK)
rearrangement in surgically resected non-small cell lung cancer (NSCLC). Methods ALK …

In 2011, the Vysis Break Apart ALK fluorescence in situ hybridization (FISH) assay was
approved by the United States Food and Drug Administration as a companion diagnostic for …